Syndax Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the …

Biotechnology
US, Waltham [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Syndax Pharmaceuticals, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Syndax Pharmaceuticals, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Syndax Pharmaceuticals, Inc..

End of SNDX's Analysis
CIK: 1395937 CUSIP: 87164F105 ISIN: US87164F1057 LEI: - UEI: -
Secondary Listings
SNDX has no secondary listings inside our databases.